ATE491456T1 - Verfahren und zusammensetzungen zur verringerung der neurodegeneration bei amyotrophischer lateralsklerose - Google Patents

Verfahren und zusammensetzungen zur verringerung der neurodegeneration bei amyotrophischer lateralsklerose

Info

Publication number
ATE491456T1
ATE491456T1 AT05820886T AT05820886T ATE491456T1 AT E491456 T1 ATE491456 T1 AT E491456T1 AT 05820886 T AT05820886 T AT 05820886T AT 05820886 T AT05820886 T AT 05820886T AT E491456 T1 ATE491456 T1 AT E491456T1
Authority
AT
Austria
Prior art keywords
solution
aqueous
compositions
methods
lateral sclerosis
Prior art date
Application number
AT05820886T
Other languages
English (en)
Inventor
Seo Hong Yoo
Original Assignee
Seo Hong Yoo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seo Hong Yoo filed Critical Seo Hong Yoo
Application granted granted Critical
Publication of ATE491456T1 publication Critical patent/ATE491456T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AT05820886T 2004-11-01 2005-10-31 Verfahren und zusammensetzungen zur verringerung der neurodegeneration bei amyotrophischer lateralsklerose ATE491456T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62410004P 2004-11-01 2004-11-01
US62842104P 2004-11-16 2004-11-16
PCT/US2005/039089 WO2006050165A2 (en) 2004-11-01 2005-10-31 Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis

Publications (1)

Publication Number Publication Date
ATE491456T1 true ATE491456T1 (de) 2011-01-15

Family

ID=36072042

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05820886T ATE491456T1 (de) 2004-11-01 2005-10-31 Verfahren und zusammensetzungen zur verringerung der neurodegeneration bei amyotrophischer lateralsklerose

Country Status (10)

Country Link
US (1) US20060142241A1 (de)
EP (2) EP2255812A1 (de)
JP (1) JP2008518935A (de)
KR (1) KR101358078B1 (de)
AT (1) ATE491456T1 (de)
AU (1) AU2005302452B2 (de)
CA (1) CA2585471A1 (de)
DE (1) DE602005025391D1 (de)
IL (1) IL182805A (de)
WO (1) WO2006050165A2 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772220B2 (en) 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US20050158408A1 (en) * 1998-07-24 2005-07-21 Yoo Seo H. Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
US20070072828A1 (en) * 1998-07-24 2007-03-29 Yoo Seo H Bile preparations for colorectal disorders
US7303768B2 (en) * 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US7145125B2 (en) 2003-06-23 2006-12-05 Advanced Optical Technologies, Llc Integrating chamber cone light using LED sources
CA2533369C (en) 2003-07-22 2009-07-14 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
EP1789057B1 (de) 2004-08-30 2010-02-24 Seo Hong Yoo Nervenschutzwirkung von aufgelöster udca bei einem fokalen ischämischen modell
WO2006044771A2 (en) 2004-10-15 2006-04-27 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US20090253782A1 (en) * 2006-07-18 2009-10-08 Ratan Rajiv R Compounds for Enhancing Arginase Activity and Methods of USe Thereof
WO2008036410A2 (en) * 2006-09-20 2008-03-27 Medivation Neurology, Inc. Methods and compositions for treating amyotrophic lateral sclerosis (als)
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
US8097633B2 (en) 2006-11-15 2012-01-17 Rich Steven A Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium
US8969402B2 (en) 2006-11-15 2015-03-03 Steven A. Rich Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
US9034890B2 (en) * 2006-11-15 2015-05-19 Steven A. Rich Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
GB0708507D0 (en) 2007-05-02 2007-06-13 Queen Mary & Westfield College Substituted phosphonates and their use
EP2190844B3 (de) 2007-08-15 2013-07-17 Arena Pharmaceuticals, Inc. Imidazo[1,2-a]pyridinderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich für die behandlung von damit in zusammenhang stehenden erkrankungen eignen
GB0805862D0 (en) * 2008-04-01 2008-04-30 Bioalvo Servi Os Investiga Oo Method
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2009126332A2 (en) * 2008-04-11 2009-10-15 Teva Pharmaceutical Industries, Ltd. Method for treatment of amyotrophic lateral sclerosis using talampanel
RU2374245C1 (ru) * 2008-08-22 2009-11-27 Андрей Александрович Иващенко Лиганд с широким спектром одновременной рецепторной активности, фармацевтическая композиция, способ ее получения и лекарственное средство
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
TR201805216T4 (en) 2008-10-28 2018-06-21 Arena Pharm Inc COMPOSITIONS OF A USEFUL 5-HT2A SEROTONINE RECEPTOR MODULATOR FOR THE TREATMENT OF RELATED DISORDERS
GB2465228A (en) * 2008-11-15 2010-05-19 Athena Health Patents Inc Analogues of phloroglucinols from eucalyptus plant varieties and related compounds and their use in treating neurodegenerative disorders
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2010086864A1 (en) * 2009-02-02 2010-08-05 Galmed International Ltd. Methods and compositions for treating alzheimer's disease
WO2011028794A2 (en) * 2009-09-01 2011-03-10 Lazarus Therapeutics, Inc. Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
RU2567661C2 (ru) 2009-09-01 2015-11-10 Лз Терапьютикс, Инк. Способы выделения и очистки ганглиозидов
EP2422787A1 (de) * 2010-08-17 2012-02-29 Neurotec Pharma, S.L. Diazoxid zur Verwendung bei der Behandlung von amyotropher Lateralsklerose (ALS)
WO2012138003A1 (ko) * 2011-04-08 2012-10-11 경북대학교 산학협력단 탈황산화된 헤파린-담즙산 유도체의 염증성 질환의 예방 및 치료 용도
EP2804871B1 (de) 2012-01-20 2017-04-12 Garnet BioTherapeutics, Inc Verfahren zur herstellung von gangliosiden
CA3111941A1 (en) 2012-10-25 2014-05-01 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
KR102001957B1 (ko) * 2013-02-25 2019-07-19 한국화학연구원 8-하이드록시-7-아이오도-5-퀴놀린설폰산 또는 1-(2,4,6-트리하이드록시페닐)프로판-1-온을 유효성분으로 포함하는 암 치료 또는 예방용 약학적 조성물
PL3461834T3 (pl) 2013-03-13 2021-12-27 Sage Therapeutics, Inc. Neuroaktywne steroidy
US9872865B2 (en) * 2013-03-24 2018-01-23 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
PL3016654T3 (pl) * 2013-07-01 2019-02-28 Bruschettini S.R.L. Kwas tauroursodeoksycholowy (TUDCA) do zastosowania w leczeniu zaburzeń neurodegeneracyjnych
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
CN110305095A (zh) 2013-10-22 2019-10-08 综合医院公司 色甘酸衍生物以及成像和治疗的相关方法
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3169315B1 (de) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Missbrauchssichere flüssigkeitsfülldosierform mit unmittelbarer freisetzung
CA2964628A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
JP6048599B2 (ja) * 2015-05-20 2016-12-21 ゼリア新薬工業株式会社 内用液剤
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
EP3307250B1 (de) 2015-06-15 2022-11-23 QAAM Pharmaceuticals, LLC Glycopyrroniumfettsäuresalze und verfahren zur herstellung
KR101743960B1 (ko) 2015-07-06 2017-06-08 서울대학교산학협력단 G단백질 결합형 수용체19 작용제를 유효성분으로 함유하는 알츠하이머 질환 또는 치매를 예방, 치료 또는 지연하기 위한 약학적 조성물
MX2018000280A (es) 2015-07-06 2018-03-08 Sage Therapeutics Inc Oxiesteroles y metodos de uso de los mismos.
RU2018103338A (ru) 2015-07-15 2019-08-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины для профилактики и лечения галлюцинаций, ассоциированных с нейродегенеративным заболеванием
AU2017240157B2 (en) 2016-04-01 2022-10-20 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CN116889562A (zh) * 2016-08-31 2023-10-17 通用医疗公司 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞
FR3055548B1 (fr) 2016-09-05 2018-09-28 Metabrain Research Utilisation de metabolites du tryptophane dans le traitement de l'atrophie musculaire
US10300077B2 (en) * 2016-09-12 2019-05-28 Steven Hoffman Compositions and methods for treating dementia
KR20180036580A (ko) * 2016-09-30 2018-04-09 주식회사 유스바이오팜 수가용화(水加溶化)된 우르소데옥시콜산을 함유하는 염증성 피부질환 또는 중증 소양증 예방 또는 치료용 조성물
WO2018064649A1 (en) 2016-09-30 2018-04-05 Sage Therapeutics, Inc. C7 substituted oxysterols and methods as nmda modulators
WO2018075699A1 (en) 2016-10-18 2018-04-26 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
KR102252450B1 (ko) * 2017-02-09 2021-05-14 주식회사 아미코젠파마 우르소데옥시콜산을 함유하는 시각장애 예방 또는 치료용 조성물
KR101953298B1 (ko) * 2017-07-18 2019-02-28 의료법인 성광의료재단 우르소데옥시콜산을 함유하는 염증성 질환 또는 척수 손상 예방 또는 치료용 조성물
KR102089397B1 (ko) * 2018-03-02 2020-03-16 충북대학교 산학협력단 미코나졸을 유효성분으로 포함하는 퇴행성 중추신경계 질환의 예방 또는 치료용 약학 조성물
KR20210071943A (ko) 2018-07-02 2021-06-16 더 제너럴 하스피탈 코포레이션 크로몰린 소듐 및 α-락토스의 분말화된 제형
JP2021530543A (ja) * 2018-07-22 2021-11-11 バイオヘイブン・セラピューティクス・リミテッドBiohaven Therapeutics Ltd. アルツハイマー病を処置するためのリルゾールプロドラッグの使用
CN109655544B (zh) * 2018-12-25 2022-08-12 广东华南药业集团有限公司 一种盐酸二甲双胍及其制剂的质量控制方法
CN112569243A (zh) * 2019-09-30 2021-03-30 神农医药科技有限公司 制备治疗阿尔茨海默病的药物
WO2021126320A1 (en) * 2019-12-16 2021-06-24 Amylyx Pharmaceuticals Inc. Treatment of amyotrophic lateral sclerosis
US11583542B2 (en) 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
KR102089411B1 (ko) * 2020-02-27 2020-03-16 충북대학교 산학협력단 미코나졸을 유효성분으로 포함하는 퇴행성 중추신경계 질환의 예방 또는 치료용 약학 조성물
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
US10905698B1 (en) * 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
EP4289431A1 (de) 2020-11-19 2023-12-13 Gliacelltech Inc. Didanosin enthaltende zusammensetzung zur prävention oder behandlung von neuroinflammatorischen erkrankungen
JP2024517724A (ja) * 2021-04-27 2024-04-23 アニマスキュア インコーポレイテッド． オキシカム系化合物を含む筋疾患の予防または治療用組成物
CN113318222B (zh) * 2021-07-15 2022-05-06 济宁医学院 超氧化物歧化酶在制备治疗银屑病药物中的应用及方法
CN115721605B (zh) * 2021-08-31 2024-05-24 成都倍特药业股份有限公司 一种硫酸阿托品液体制剂及其制备方法
KR20230136027A (ko) * 2022-03-16 2023-09-26 주식회사 플루토 Alox5 억제제를 포함하는 근감소증 예방 또는 치료용 조성물
WO2024028324A1 (en) * 2022-08-03 2024-02-08 Institut National De La Sante Et De La Recherche Medicale Molecules for the prevention and treatment of neuromuscular disorders

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4092428A (en) * 1973-11-02 1978-05-30 Yamanouchi Pharmaceutical Co., Ltd. Process of preparing stable prostaglandin E group-containing formulation
US4036954A (en) * 1973-11-02 1977-07-19 Yamanouchi Pharmaceutical Co., Ltd. Stable prostaglandin E group-containing formulation
US4113882A (en) * 1974-10-21 1978-09-12 Yamanouchi Pharmaceutical Co., Ltd. Stabilized oral prostaglandin formulation and the process for the preparation thereof
US4320146A (en) * 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
GB8313217D0 (en) * 1983-05-13 1983-06-22 Glaxo Group Ltd Pharmaceutical compositions
GB8417895D0 (en) * 1984-07-13 1984-08-15 Marples B A Pharmaceutical anti-fungal composition
GB8608335D0 (en) * 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
HU203204B (en) * 1987-09-15 1991-06-28 Sandoz Ag Process for producing suppository containing calcitonin and taurocholic acid
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
US5446026A (en) * 1989-08-09 1995-08-29 Advanced Peptides & Biotechnology Sciences Potent non-opiate analgesic
US5157022A (en) * 1989-11-22 1992-10-20 Adrian Barbul Method for reducing blood cholesterol using arginine
AU658565B2 (en) * 1990-04-04 1995-04-27 Berwind Pharmaceutical Services, Inc. Aqueous maltodextrin and cellulosic polymer film coatings
US5057321A (en) * 1990-06-13 1991-10-15 Alza Corporation Dosage form comprising drug and maltodextrin
IT1245890B (it) * 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari.
IT1245891B (it) * 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche a rilascio controllato per uso orale gastroresistenti contenenti acidi biliari e loro sali.
IT1245889B (it) * 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche per uso orale gastroresistenti contenenti sali di acidi biliari.
CH680704A5 (de) * 1991-05-15 1992-10-30 Medichemie Ag
HU209251B (en) * 1992-03-13 1994-04-28 Synepos Ag Process for producing stable, peroral solution drug forms with controlled release of active ingredient and comprising beta-blocking pharmacons
US5292534A (en) * 1992-03-25 1994-03-08 Valentine Enterprises, Inc. Sustained release composition and method utilizing xanthan gum and an active ingredient
US5342934A (en) * 1992-06-19 1994-08-30 The Trustees Of Columbia University In The City Of New York Enantioselective receptor for amino acid derivatives, and other compounds
US5260074A (en) * 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5578304A (en) * 1992-06-22 1996-11-26 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5302400A (en) * 1992-06-22 1994-04-12 Digestive Care Inc. Preparation of gastric acid-resistant microspheres containing digestive enzymes and buffered-bile acids
US5977070A (en) * 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
US5346701A (en) * 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
AU683049B2 (en) * 1993-03-31 1997-10-30 Mitsubishi-Tokyo Pharmaceuticals, Inc. Cholestasis ameliorant
WO1995003056A1 (fr) * 1993-07-19 1995-02-02 Tokyo Tanabe Company Limited Inhibiteur de proliferation du virus de l'hepatite c
DK0640344T3 (da) * 1993-08-30 1999-07-05 Medichemie Ag Ursodesoxycholsyreholdigt lægemiddel i flydende administreringsform
GB9405833D0 (en) * 1994-03-24 1994-05-11 Pfizer Ltd Separation of the enantiomers of amlodipine
DE4432708A1 (de) * 1994-09-14 1996-03-21 Hoechst Ag Modifizierte Gallensäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
US5965164A (en) * 1994-10-28 1999-10-12 Fuisz Technologies Ltd. Recipient-dosage delivery system
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5686588A (en) * 1995-08-16 1997-11-11 Yoo; Seo Hong Amine acid salt compounds and process for the production thereof
US5843929A (en) * 1996-03-22 1998-12-01 Mayo Foundation For Medical Education And Research Chemoprevention of metachronous adenomatous colorectal polyps
JP2000507938A (ja) * 1996-03-22 2000-06-27 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 結腸直腸の化学的保護のためのウルソデオキシコール酸化合物及びｎｓａｉｄの組合せ
US6596712B2 (en) * 1996-04-26 2003-07-22 Genaera Corporation Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
US5750104A (en) * 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
US5898028A (en) * 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
DE29717252U1 (de) * 1997-09-26 1998-02-19 Dr. Falk Pharma GmbH, 79108 Freiburg Arzneimittelkit aus einem Budesonid-haltigen und einem Ursodesoxycholsäure-haltigen Arzneimittel zur Behandlung von cholestatischen Lebererkrankungen
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
KR100314496B1 (ko) * 1998-05-28 2001-11-22 윤동진 항혈전성이 있는 헤파린 유도체, 그의 제조방법 및 용도
US6407117B1 (en) * 1998-06-18 2002-06-18 The George Washington University Method of administering camptothecin compounds for the treatment of cancer with reduced side effects
US7303768B2 (en) * 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US20050158408A1 (en) * 1998-07-24 2005-07-21 Yoo Seo H. Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
US7772220B2 (en) * 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US6251428B1 (en) * 1998-07-24 2001-06-26 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US20070072828A1 (en) * 1998-07-24 2007-03-29 Yoo Seo H Bile preparations for colorectal disorders
US6210699B1 (en) * 1999-04-01 2001-04-03 Watson Pharmaceuticals, Inc. Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US7034006B2 (en) * 2000-01-10 2006-04-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of disease
CN100558407C (zh) 2000-02-04 2009-11-11 柳署弘 制备含有胆汁酸的澄清水溶液剂型
CA2415156A1 (en) * 2000-07-18 2002-01-24 The Nutrasweet Company Drying of neotame with co-agents
US20030044413A1 (en) * 2000-08-15 2003-03-06 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
WO2004012686A2 (en) 2002-08-06 2004-02-12 Nitromed, Inc. Nitrosated and/or nitrosylated ursodeoxycholic acid compounds, compositions and methods of use
US20060204481A1 (en) * 2003-04-02 2006-09-14 Steer Clifford J Methods of promoting cell viability
EP1789057B1 (de) * 2004-08-30 2010-02-24 Seo Hong Yoo Nervenschutzwirkung von aufgelöster udca bei einem fokalen ischämischen modell
WO2006044771A2 (en) * 2004-10-15 2006-04-27 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound

Also Published As

Publication number Publication date
EP2255812A1 (de) 2010-12-01
WO2006050165A3 (en) 2006-07-06
WO2006050165A2 (en) 2006-05-11
AU2005302452B2 (en) 2010-12-09
EP1814558A2 (de) 2007-08-08
DE602005025391D1 (de) 2011-01-27
AU2005302452A1 (en) 2006-05-11
CA2585471A1 (en) 2006-05-11
KR101358078B1 (ko) 2014-02-06
IL182805A0 (en) 2008-04-13
JP2008518935A (ja) 2008-06-05
IL182805A (en) 2012-10-31
EP1814558B1 (de) 2010-12-15
KR20070089926A (ko) 2007-09-04
US20060142241A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
ATE491456T1 (de) Verfahren und zusammensetzungen zur verringerung der neurodegeneration bei amyotrophischer lateralsklerose
HRP20171270T1 (hr) Liofilizirani spoj
WO2009019571A3 (fr) Procede de solubilisation d'huiles essentielles dans l'eau
EP2270056A3 (de) Reinigung von Streptococcus-kapselpolysaccharid
WO2006003290A3 (fr) Derives depolymerises sulfates d'exopolysaccharides (eps) preparation et utilisations
EA031355B1 (ru) Композиции на основе сульфоалкильных эфиров циклодекстрина и способы их получения
WO2009098715A3 (en) Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents
MD20070267A (en) Gastroresistant pharmaceutical formulation containing rifaximin
ATE540684T1 (de) Zubereitung und verfahren zur regulierung und aufrechterhaltung der vaginalen bakterienflora und der normalen acidität in der vagina
DE60109036T2 (de) Absorbierende Artikel für Frauen mit gelbildenden Polysaccharid-enthaltenden Flügeln
WO2010149363A3 (en) Pharmaceutical composition comprising rotigotine salts (acid or na), especially for iontophoresis
CN103705535A (zh) 壳聚糖妇科凝胶及其制备方法
WO2007064968A3 (en) Stable pharmaceutical compositions of 5,10 methylenetetrahydrofolate
JP6695809B2 (ja) 毛乳頭細胞活性化剤
CN1969801A (zh) 水溶性壳聚糖在牙膏和漱口水中的应用
CN102952281A (zh) 一种壳寡糖和透明质酸交联凝胶的制备方法
TW200734295A (en) Alkyl-resorcinol glycoside, process for production of the same, and use of the same
UA95224C2 (ru) Антацидная фармацевтическая композиция в порошковой форме, фармацевтическое средство, ее содержащее, и способ ее получения
WO2006110810A3 (en) Polymorphs of 3-o-(3',3'-dimethylsuccinyl) betulinic acid di-n-methyl-d-glucamine
WO2007044348A3 (en) Anti-infective hygiene products based on cellulose acetate phthalate
JP5349744B2 (ja) ミネラル吸収促進剤、食品及び飼料
Dongre Marine polysaccharides in medicine
JP4840298B2 (ja) キトサン配合飲料
EP1108429A3 (de) Verbesserte Aminosäurenzusammensetzung zum Bereitstellen von Aminosäurenergänzungen oder Eiweissersatz, insbesondere zur Behandlung und/oder Verwaltung von bestimmten Erkrankungen
CN109646325A (zh) 两亲性羧甲基壳聚糖的制备方法及其在护理洗液的应用

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties